EDG-7500
EDG-7500-106
Phase 1 small_molecule active
Quick answer
EDG-7500 for Hepatic Impairment (HI) is a Phase 1 program (small_molecule) at Edgewise Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Edgewise Therapeutics
- Indication
- Hepatic Impairment (HI)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active